UnitedHealthcare IVF coverage policy: step therapy, PGT-A, and what gets denied (2026)
Policy: UHC Commercial Medical Policy 2026T0270NN — Infertility Diagnosis, Treatment, and Fertility Preservation (eff. 2026-06-01); medical necessity criteria live in the Optum 'Fertility Solutions Medical Necessity Clinical Guideline: Infertility' (eff. 2026-06-10); PGT governed by UHC Medical Policy 2026T0597Q 'Preimplantation Genetic Testing and Related Services' (eff. 2026-05-01). This is the clinical policy your clinic's authorization team is arguing against. Knowing it before you start avoids the most common denials.
Step therapy (IUI before IVF)
Not a hard requirement. The UHC medical policy lists ovulation induction, IUI and ART as separately covered services with no stated dependency. The Optum clinical guideline is prognosis-based rather than a hard IUI gate: 'Females under 35 may initially be addressed with a limited (≤3) number of clomiphene IUI cycles but should progress rapidly to ART' and 'Females aged 35 and older should be advised to move directly to IVF.' In practice Optum reviewers may still ask for prior-treatment history for unexplained infertility in members under 35 (EasyRCM lists 'missing failed treatment history' as a top denial reason), so treat the ≤3 IUI language as a soft expectation rather than a policy requirement.
Ovarian reserve and age thresholds
- Optum guideline: 'FSH level ≥ 10 mIU/ml' = diminished ovarian reserve; 'FSH level ≥ 15 mIU/ml' = very poor/futile prognosis marker ('FSH levels should be evaluated in conjunction with additional predictors')
- Optum guideline: 'AMH level < 1.0 ng/ml' = diminished ovarian reserve; 'AMH level < 0.2 ng/ml' = futile prognosis marker (two or more markers needed to deny on futility)
- Optum guideline: 'Antral follicle count < 7' = diminished ovarian reserve; 'Antral follicle count < 3' = very poor prognosis marker
- Optum guideline: 'An estradiol level <100 pg/ml/follicle ≥15 mm in diameter' during stimulation = continued treatment not indicated
- Optum guideline: ART with autologous oocytes not indicated 'in the setting of a very poor or futile prognosis'; ART with autologous or donor oocytes not indicated 'in female recipients who are ≥55 years of age'
- UHC medical policy itself sets no numeric FSH/AMH/age cutoff and cites ASRM 2020 that ovarian reserve markers 'should not be used as a fertility test'
Considered experimental / not medically necessary
- PGT-A: UHC Policy 2026T0597Q — 'unproven and not medically necessary for all other populations and conditions due to insufficient evidence of efficacy' (only PGT-M/PGT-SR for a single-gene or structural-rearrangement risk causing 'Significant Health Problems or Severe Disability' is covered); Optum guideline: 'Pre-implantation genetic testing for aneuploidy is not indicated'
- PGT-P (polygenic): 'not indicated'
- Endometrial receptivity testing (ERA): UHC lists 'Uterine/endometrial receptivity testing' as unproven; Optum: 'insufficient evidence to support routine use'
- Treatments to improve endometrial receptivity (immunotherapy, endometrial scratching, IVIG, intralipid, PRP)
- Assisted hatching: Optum — 'not indicated/medically necessary'
- ICSI without a qualifying indication: Optum lists ICSI as NOT indicated for 'Unexplained infertility', 'Advanced maternal age', 'Low oocyte yield', 'isolated teratospermia', or 'Routine IVF'
- Sperm DNA integrity/fragmentation tests; hyaluronan binding assay; computer-assisted sperm analysis
- Coculture of embryos; EmbryoGlue; in vitro maturation of oocytes; cryopreservation of immature oocytes, ovarian or testicular tissue (outside covered iatrogenic fertility preservation)
- Adjuncts: DHEA, testosterone pretreatment, growth hormone, aspirin, heparin, antioxidants, seminal plasma (Optum: not indicated)
Prior authorization required for
- IVF and related services ('we'll continue to require prior authorization for IVF and related services' — UHC CA notice; requests via UnitedHealthcare Provider Portal or Optum Fertility Solutions when delegated)
- Each fresh retrieval cycle (authorized one cycle at a time)
- Each frozen embryo transfer (separate authorization; embryo status report and transfer plan requested — third-party source)
- ICSI (must meet an Optum indication)
- PGT-M / PGT-SR (separate genetic-testing prior authorization under 2026T0597Q)
- Fertility medications via Optum Rx specialty pharmacy
- Iatrogenic fertility preservation (separate benefit review)
Billing quirks that cause denials
- UHC's Applicable Codes table recognizes HCPCS case-rate S-codes (S4015 'Complete in vitro fertilization cycle, not otherwise specified, case rate', S4016 frozen cycle, S4018 FET cancelled before transfer, S4020 IVF cancelled before aspiration, S4022 assisted oocyte fertilization case rate) alongside component CPTs (58970, 58974, 89250, 89280/89281). Whether a clinic bills the global S-code or unbundled components is contract-driven; a clinic contracted on S4015 that also bills 58970/89250 separately will see the component lines denied as included in the case rate (third-party billing guides call this a 'global period conflict').
- Cycle monitoring (E/M, 76857 ultrasounds, estradiol/LH labs) may or may not be inside the global rate — EasyRCM: 'Confirm whether monitoring is bundled in the IVF global code or must be billed separately per plan contract.' Not stated in UHC's published policy; confidence low.
- Cancelled cycles have their own case-rate codes (S4020 before aspiration; S4018 FET cancelled before transfer) — a cancelled stimulation billed as a full S4015 will be reduced or denied.
- PGT embryo biopsy (89290/89291) and PGT lab codes (0552U–0555U) are adjudicated under the separate PGT policy 2026T0597Q, not the infertility policy; PGT-A claims deny as unproven even when the IVF cycle is authorized.
- Codes marked with an asterisk in the UHC table (58970, 89250, 89253, 89280/89281) 'apply to fertility preservation for Iatrogenic Infertility benefit' — the iatrogenic fertility-preservation benefit is administered separately from the infertility benefit and may exist on plans with no IVF benefit.
- Fertility benefits are often delegated to Optum Fertility Solutions; authorizations submitted to UHC instead of Optum (or vice versa) are a leading cause of delay/denial (third-party source).
Appeal tips
- Age 35+ denial for 'insufficient prior treatment': quote the Optum Fertility Solutions guideline verbatim — 'Females aged 35 and older should be advised to move directly to IVF' — and attach the two most recent semen analyses / tubal imaging / AMH so the reviewer cannot recharacterize the case as unexplained infertility under 35.
- ICSI denial: UHC/Optum approves ICSI only for a listed indication. Document 'alteration in sperm concentration and/or motility and/or morphology in at least two sperm analyses', prior conventional fertilization <50%, cryopreserved oocytes, TESE/PESA sperm, or a covered PGT-M/PGT-SR cycle; ICSI for 'unexplained infertility', 'advanced maternal age' or 'low oocyte yield' will not be overturned on internal appeal.
- PGT-A denial: UHC's PGT policy calls PGT-A 'unproven and not medically necessary' for every non-hereditary indication, so internal appeals nearly always fail. If the plan is fully insured, request the state external review (or DOL/independent review for self-funded ERISA plans) on a medical-necessity basis with SART/ASRM literature; if a monogenic or structural-rearrangement risk exists, re-file as PGT-M/PGT-SR with genetic counseling notes, which is a covered indication.
- Global-billing denials (component CPTs denied as 'included in case rate'): ask the clinic to confirm its UHC contract's IVF case-rate structure and resubmit with S4015/S4016 or the correct cancelled-cycle code (S4020/S4018); this is a coding correction, not a medical-necessity appeal.
- Always confirm first whether the fertility benefit is administered by UHC or by Optum Fertility Solutions (the member ID card / member services); a denial for 'no authorization on file' is frequently just a misrouted request and is fixed by resubmitting to the right entity rather than appealing.